Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Acticor Biotech | October 05, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke
Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy). 5 cohorts of patients presenting with an acute ischemic stroke episode of moderate to severe intensity were enrolled in this study and randomly received glenzocimab at one of 4 ascending doses or a placebo, in a blind fashion as a 6-hour single-dose infusion. Patients were evaluated continuously for 24 hours, then 7 and 90 days after the episode. Approximately 50% were also treated with the thrombolytic agent rtPA (ACTILYSE®), and the other 50% received rtPA and underwent a mechanical thrombectomy. The DSMB met on 5 occasions in between each cohort and at the end of the last administration, and they analyzed the safety data with a particular focus on the advent of intra-cerebral hemorrhages and other bleeding related events. The last analysis performed after the target dose of 1000mg had been administered to 12 patients confirmed both the absence of increased bleeding when glenzocimab is added to rtPA and to rtPA and thrombectomy, and the absence of any dose-related trend in the number and nature of adverse events recorded.

Spotlight

This is a video for Mr. Scully's biotechnology project. Our topic was stem cells.

Related News

MEDICAL

Mogrify announces Exploratory Research Collaboration with MRC Laboratory of Molecular Biology

Mogrify | January 11, 2021

Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstructing to help improve the creation of proteins which are not delivered adequately well in existing articulation frameworks. The MOGRIFY® technology will be applied to foresee mixes of record variables to incite trans-separation starting with one cell type then onto the next. The subsequent objective cell types could give analysts improved admittance to significant proteins found in human cell types that are hard to get and take into consideration more efficient protein production. Mogrify will get admittance to any licensed innovation and skill created during the undertaking, further empowering the commercialization of the innovation in regions of remedial worth. This coordinated effort is a development of the Company's relationship with the MRC LMB and follows the declaration in December 2020 that it had made sure about a restrictive permit from the MRC LMB to an upgraded form of MOGRIFY technology empowering more precise record factor expectations and improved cell transformation viability. In the interest of the MRC, the clinical exploration noble cause LifeArc encouraged the restrictive permit of the new form of Mogrify's center reconstructing stage, and together arranged the legitimate structure to empower a fruitful cooperation between the MRC and Mogrify.

Read More

INDUSTRY OUTLOOK

Andelyn Biosciences Selects TetraScience as a Strategic Partner for Innovation in Therapeutics Development and Manufacturing

Andelyn Biosciences | August 26, 2021

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additionally, Andelyn customers will benefit from secure, convenient access to harmonized data that is prepared for analytics and visualization. As a Contract Development and Manufacturing Organization (CDMO) for cell and gene therapies, Andelyn must remain GMP-compliant and increase efficiency while leading the industry in the innovative services they provide to customers. By launching a Connected Plant, Andelyn will gain autonomous operation, predictive capabilities, improved process monitoring and control, and increased data integrity. "Andelyn has been a pioneer in gene therapy with a 15-year history accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients," said Bryan J. Holmes, Vice President, Information Technology at Andelyn Biosciences. "Together with TetraScience, we're transforming how we work with our clients, utilizing fully-digitized, cloud-native services to help connect all the plant and lab data created during complex development and manufacturing cycles." Andelyn chose TDP for its unique ability to harmonize data from building & facilities systems, lab instruments, and process & manufacturing equipment. By replatforming the data to a future-proof managed cloud environment, Andelyn will benefit from enhanced GMP compliance and data integrity, improved time-to-value, and lower TCO. Additionally, with an open data cloud platform powered by TDP and the Tetra Partner Network, Andelyn will be able to leverage their preferred tooling for analytics while supporting their customers' data consumption needs. "We're excited to partner with Andelyn Biosciences on their mission-critical data cloud initiative and accelerate their journey towards becoming a digital company," stated Chad Garrett, TetraScience CRO. "As an innovator in providing cloud-native development and manufacturing services to its customers, Andelyn Biosciences recognizes that harmonizing scientific data in the cloud and making it easily accessible to clients will transform the way CDMOs exchange data with clients." Andelyn's initial deployment of TDP is focused on acquiring and harmonizing historical data across key sources while enabling enhanced data search capabilities. Moving forward, Andelyn expects to complete the rollout of the Connected Plant with additional data sources and instruments, and ultimately launch a groundbreaking digital CDMO experience for their customers. About Andelyn Biosciences, Inc. Andelyn Biosciences is a pioneering gene therapy company born out of Nationwide Children's Hospital, where the first FDA-approved systemic gene therapy was discovered. Andelyn is named in honor of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children's Hospital 8-year-old Andrew and 8-week-old Evelyn. Bringing together more than 15 years of experience in AAV vector manufacturing, Andelyn is a full-spectrum Contract Development Manufacturing Organization (CDMO) that helps pioneer solutions that turn hope into reality. Our mission is to accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients. We accomplish this by bringing scalability, capacity, efficiency and expert resources to manufacturing matrices, all to advance the development of viral vector-based therapeutics. Our capabilities include viral vector process and analytical development, small to large scale GMP manufacturing, fill/finish and QC/QA release testing through Phase III with plans to launch commercial services in 2022. Andelyn also offers plasmid manufacturing services, formulation development services and regulatory support.

Read More

MEDTECH

Biotech Start-Up Aanika Biosciences Lands Initial $12M Funding for Cutting-Edge Food Tracing Technology

Aanika Biosciences | December 01, 2021

Biotech start-up Aanika Biosciences today announced the initial closing of its $12 million Series A round, led by Jon Cholak of Adit Ventures along with existing investors Draper Associates and SOSV. The investment will help scale the company’s food tracing technology platform, advance research and expand its Brooklyn food safety and manufacturing facility to approximately 30,000 square feet. Aanika's proprietary technology is designed to accelerate the speed and accuracy of how food safety issues are handled. The platform, which uses edible microbial ‘tags,’ has already been tested on leafy greens and has the potential to be applied to other foods and ingredients including oils, coffee, meats and grains. “Innovation in food safety is long overdue, and there couldn’t be a more important time to bring a technology like this to the market. The pandemic has truly exposed the fragility of our supply chain. Being able to expand and build out our capability will give farmers, insurers, food companies and consumers an added layer of transparency and security, as well as minimize the economic and environmental impact of food recalls.” Dr. Ellen Jorgensen, Chief Science Officer for Aanika The technology enables farmers to 'watermark' crops with edible, food-friendly microbes that can be detected at any point in the product’s journey through the supply chain, so that when there is a case of foodborne illness it can be traced directly to the source. “Foodborne illness impacts over 50 million people and costs the U.S. tens of billions of dollars a year. Our technology can help minimize the impact and we are developing solutions that may prevent it from happening in the first place,” said co-founder and CEO of Aanika, Vishaal Bhuyan. “Identifying the origin of food recalls is just the start of what this platform can do. We are excited to see how far we can push our microbial technology to add value in the form of combating contamination, increasing nutritional content and supporting crop health. We are also exploring how our technology can even revolutionize agricultural insurance underwriting. All of this is driven by the power of biology.” "We believe Aanika could transform the food system as their traceability technology can integrate with the blockchain and ensure high quality data from end-to-end,” said Tim Draper, Founder and Managing Partner of Draper Associates. About Aanika Biosciences Aanika Biosciences was co-founded in 2018 by Vishaal Bhuyan after he personally experienced the consequences of ordering fresh, ethically sourced seeds and receiving stale, contaminated products instead. He made it is his mission to create a safer food supply by finding a way to track, trace and authenticate products. Aanika’s customized microbial-based tags help companies gain valuable insights about their supply chains, help their customers make better consumption choices, and create a more sustainable world.

Read More

Spotlight

This is a video for Mr. Scully's biotechnology project. Our topic was stem cells.